Previous Article | Next Article ![]()
Eukaryotic Cell, October 2006, p. 1674-1687, Vol. 5, No. 10
1535-9778/06/$08.00+0 doi:10.1128/EC.00252-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
,
Department of Biological Sciences, The University of Iowa, Iowa City, Iowa 52242,1 Department of Molecular, Cellular, and Developmental Biology,2 Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 065113
Received 7 August 2006/ Accepted 18 August 2006
|
|
|---|
2 complex
represses white-opaque switching, as well as mating. Based upon the
assumption that the a1-
2 corepressor complex binds to
the gene that regulates white-opaque switching, a chromatinimmunoprecipitation-microarray analysis strategy was used to identify
52 genes that bound to the complex. One of these genes, TOS9,
exhibited an expression pattern consistent with a "master
switch gene." TOS9 was only expressed in opaque cells,
and its gene product, Tos9p, localized to the nucleus. Deletion of the
gene blocked cells in the white phase, misexpression in the white phase
caused stable mass conversion of cells to the opaque state, and
misexpression blocked temperature-induced mass conversion from the
opaque state to the white state. A model was developed for the
regulation of spontaneous switching between the opaque state and the
white state that includes stochastic changes of Tos9p levels above and
below a threshold that induce changes in the chromatin state of an
as-yet-unidentified switching locus. TOS9 has also been
referred to as EAP2 and
WOR1. |
|
|---|
laboratory strain could not switch, MTLa1 and
MTL
2 deletion derivatives of that strain, which were
and a, respectively, could. They demonstrated that
switching in the a/
strain was repressed by the
a1-
2 complex, the same complex that repressed mating
(31). Their results
suggested that in order to switch, natural strains, which are
predominantly a/
(26,
30,
48), first had to undergo
homozygosis to a/a or
/
. Lockhart et
al. (30) generalized this
observation by demonstrating that while natural a/
strains did not undergo white-opaque switching, spontaneously generated
MTL-homozygous offspring and natural
MTL-homozygous strains did switch. Miller and
Johnson (31)
further demonstrated that in order to mate, the a and
strains they derived by deleting MTL
2 and
MTLa1, respectively, first had to switch from white to
opaque. Lockhart et al.
(29) generalized this
observation by demonstrating that only natural a/a and
/
strains that expressed the opaque phenotype could
mate. The white-opaque transition, therefore, was an essential and
unique step in the C. albicans mating process
(3,
42,
43).
In spite of
the fundamental role white-opaque switching plays in mating, very
little is known about the molecular mechanisms that regulate it.
Because white-opaque switching occurs spontaneously, reversibly, and at
relatively high frequency, it has been suggested
(21,
41,
42,
46) that it may be the
result of "position-effect variegation," a metastable
change in the expression of a gene, mediated by a change in chromatin
state effected by a neighboring silent region
(12,
20,
28). This hypothesis was
supported by the observation that the deacetylase inhibitor
trichostatin A or deletion of the deacetylase gene
HDA1 or RPD3 caused increases in the frequency of
white-opaque switching
(21,
46). Directly testing
this hypothesis, however, requires identification of the site of the
switching event. Since the a1-
2 complex represses
white-opaque switching
(31), we hypothesized
that it may bind upstream of a genomic switch site, which we will refer
to for the sake of discussion as the "master switch
gene" (MSG). We therefore used a chromatinimmunoprecipitation-microarray analysis (ChIP-chip) strategy
(18,
35) to identify
a1-
2 binding sites throughout the C.
albicans genome, analyzed the transcription profiles of the
genes associated with a1-
2 binding sites to identify
candidate genes for either the MSG or an MSG activator, and finally
tested the role of candidate genes in switching by mutant analysis. We
present here the repertoire of genes that are bound by the
a1-
2 repressor complex, transcription profiles of these
genes, and mutant analyses that test the role of candidate
genes in switching. Our analysis has identified one gene,
TOS9, which exhibits characteristics consistent with an
MSG.
|
|
|---|
Generation of Myc-tagged strains.
Strains were
generated harboring the 13x Myc epitope tag at either
MTLa1 or MTL
2. The a1p and
2p transformation modules containing the CaURA3 gene
were generated by PCR with pURA3 RV-13 DNA as the template
(A. R. Borneman and M. Snyder, unpublished results) and the
80-mer C-terminal tagging primers A1RVF2 and A1RVR1 for
MTLa1p and primers P2RVF2 and P2RVR1 for
MTL
2p (see Table S2 in the supplemental material).
ura3 a/
strain CAI4
(10) was transformed with
either module, and two a1-Myc-tagged strains (a1-29.1 and
a1.29.2) and four
2-Myc-tagged strains (
2-3.1,
2-3.2,
2-4.1, and
2-8.1) were verified by
PCR for correct in-frame fusion and the number of Myc units and by
Western analysis for protein
levels.
ChIP-chip analyses. A whole-genome tiled-oligonucleotide array was used that contained 246,532 oligonucleotides 50 nucleotides in length, generated at a 60-bp spacing (10 bp between adjacent oligonucleotides) spanning the Watson strand of assembly 19 of the C. albicans genome (19). In addition, 123,271 oligonucleotides 50 nucleotides in length were designed at a 120-bp spacing (70 bp between adjacent oligonucleotides) to span the Crick strand. The start positions for the oligonucleotides on the Crick strand were generated with a 30-bp offset relative to those on the Watson strand. Arrays were synthesized on microarray slides by maskless photolithography (Nimblegen LLC, Iceland). The array design has been deposited in the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under platform number GPL4037 [NCBI GEO] .
For analysis, cells were grown in modified Lee's medium. ChIP and DNA labeling were performed as described for Saccharomyces cerevisiae (5). Hybridization was performed according to the manufacturer's (Nimblegen LLC) protocols.
The array data from three independent
immunoprecipitations for each of the
a1p::Myc and
2p::Myc strains were used for the analysis
of binding. Following array scanning, the two files corresponding to
Cy3 and Cy5 channels in pair file format were uploaded to the Tilescope
pipeline for high-density filing array analysis
(http://tilescope.gersteinlab.org;
H. Zhang et al., submitted for publication) by quantile
normalization with a window size of 400 bp, a MaxGap (the maximum gap
allowed between probes above threshold) of 60 bp, and a MinRun (the
minimum length of the region with probes above the threshold) of 120
bp. Regions corresponding to the putative transcription factor binding
site were determined with thresholds for both the signal (pseudomedian
signal,
1.15) and the P value (P < 1
x 104). Regions corresponding to the
putative transcription factor binding sites were determined with
thresholds for both the signal (pseudomedian signals,
1.15)
and the P value (P < 1 x
104). All of the raw data files for each experiment
have been deposited in GEO under series number
GSE5493
[NCBI GEO]
.
Anti-Myc immunoprecipitation of CAG1.
To test
whether the Myc-tagged a1-
2 complex bound to a known
target, cells of Myc-tagged strains a1-29.1 and
2-3.1
were lysed (16) and the
supernatant was subjected to sonication to obtain sheared chromatin
averaging 500 to 800 bp in length. The sheared chromatin was incubated
with either an anti-Myc monoclonal antibody (9E10) or a control
anti-neuron monoclonal antibody (22C10) (Developmental Studies
Hybridoma Bank, Iowa City, Iowa) at 4°C overnight. DNA was then
extracted and used for PCR amplification of the CAG1 promoter
region that spanned the a1-
2 binding site
(17). PCR amplification
was performed with primers CAGPr1and CAGPr2 (see Table S2 in the
supplemental material).
Northern analysis.
Northern analyses
were performed with either poly(A)+ mRNA or total
RNA obtained from cells of a/
strain CAI4, white and
opaque cells of
/
strains WO-1 and WUM5A, and white
and opaque cells of a/a strain P37005. For the primers
used to generate the PCR probes for Northern analysis of 51 genes
identified by ChIP-chip analysis, see Table S2 in the supplemental
material. Northern blot hybridization was performed as previously
described
(9).
Generation of TOS9 and PSO2 null mutants.
Recyclable nourseothricin resistance
(SATr) cassettes I and II, based on the maltose-inducible
flipper, were used to create null mutants of TOS9 and
PSO2 in ura3 strain WUM5A, a
derivative of
/
strain WO-1
(36,
47). The plasmid
containing the SATr cassette and strain WUM5A were generous
gifts from Joachim Morschhäuser, University of
Würzburg. Deletion cassette I was generated as described below.
Primers TOS9f1 and TOS9r1 were used to generate a 650-bp
5'-flanking region of TOS9, and primers TOS9f2 and
TOS9r2 were used to generate a 600-bp 3'-flanking region (see
Table S2 in the supplemental material). PCR products were used to
generate a 5'-3' fusion that contained the
SATr marker and lacked the entire TOS9 open reading
frame (ORF). Deletion cassette I harboring this TOS9 deletion
construct was then used to transform WUM5A
(36,
47). Two independent
transformants, TOHE1 and TOHE3, were verified as heterozygous deletion
derivatives and subjected to a POP-OUT protocol to excise the
recyclable SATr cassette. The second allele was disrupted in
TOHE3POP2, a pop-out clone of Tohe3, with deletion cassette II.
Deletion cassette II included a 350-bp 5'-flanking region
generated with primers Tos9f3 and Tos9r3 and a 300-bp
3'-flanking region generated with primers Tos9f4 and Tos9r4
(see Table S2 in the supplemental material). It lacked the 1,732-bp
TOS9 ORF. The second round of disruption resulted in
TOS9 null mutant TOHO3. PSO2 null mutant PSHO1 was
generated in a similar fashion with independent deletion cassettes I
and II. For cassette I, primers PSO2f1 and PSO2r1 were used to generate
a 5'-flanking region and primers Psof2 and Psor2 were used to
generate a 3'-flanking region (see Table S2 in the supplemental
material). For cassette II, primers 5362f3 and 5362r3 were used to
generate a 5'-flanking region and primers 5362f4 and 5362r4
were used to generate a 3'-flanking region (see Table S2 in the
supplemental material).
Generation of GFP-tagged TOS9 mutant strains. TOS9 5'- and 3'-flanking DNA was generated by PCR with primers TOGFF1and TOGFR1 in the former case and primers TOGFF2 and TOGFR2 in the latter case (see Table S2 in the supplemental material). The PCR products were digested with NsiI and subcloned into pGEM-T Easy (Promega Corp.) to derive the 5' and 3' TOS9 fusion product. The latter was cloned into the pBluescript vector (Stratagene, San Diego, CA) to derive pK22.1. The green fluorescent protein (GFP)-ORF-CaCAG1 3' fusion fragment, derived from pJ49.1 (T. Srikantha and D. R. Soll, unpublished data) was fused in frame to the 5' end of the TOS9 ORF. The plasmid vector containing the GFP ORF was a generous gift from J. Berman, University of Minnesota (11). The GFP-CAG1 fragment was amplified by PCR with primers GFCFF1 and CAGR1 (see Table S2 in the supplemental material), digested with PstI and SphI, and, together with a DNA fragment containing the nourseothricin resistance gene CaSAT1r (36), ligated between the NsiI and SphI sites to derive the plasmid derivative pK40.1, which contained the transformation module for targeting at the TOS9 locus. In-frame fusion was confirmed by sequencing, and the transformation module containing CaSAT1r was excised by XhoI digestion and used to transform strain WUM5A. Two clones, TOGF1 and TOGF4, were verified by sequencing and Southern analysis.
Tetracycline-controlled TOS9. The GFP ORF of pNIM1, a generous gift from J. Morschhäuser, University of Würzburg, was replaced with the C. albicans TOS9 ORF, obtained by PCR with strain WO-1 genomic DNA and primers 4884Sal and 4884Bgl (see Table S2 in the supplemental material). The resulting plasmid, pJ83.1, was verified by sequencing. Plasmid DNA was digested with ApaI and SacII, and the expression cassette was used to transform strain WUM5A. Transformants Wr1 and Wr2 were verified by Southern analysis. Activation by doxycycline was demonstrated by Northern analysis of TOS9.
MET3-controlled TOS9. To generate a MET3::TOS9 expression module, 665 bp of the MET3 promoter and 325 bp of the 3'-flanking region of the MET3 ORF, respectively, were amplified by PCR from WO-1 genomic DNA. Primers mesmsaf1 and mepsnrr1 were used to derive the 5'-flanking region, and mepsbgf2 and mesmsar2 were used to derive the 3'-flanking region (see Table S2 in the supplemental material). The PCR products were digested with PstI and fused by ligation-mediated cloning into plasmid pGEM-T Easy to derive pK54.2. The SATr marker DNA derived by PCR with primers SATBglf1 and SATSphr1 (see Table S2 in the supplemental material) was digested with BglII and PstI and directionally ligated to BglII-PstI-digested pK54.2 to derive pK75.2. The TOS9 ORF, derived by PCR with primers TOGSbF1 and TOSbsR1 (see Table S2 in the supplemental material), was digested with SbfI and ligated at the PstI site of pK75.2 to derive pK83.10. The orientation of the TOS9 ORF was verified by sequencing. Plasmid DNA was digested with SacII and transformed into TOS9 null mutant TOHO3. The transformants were analyzed for correct targeting at the MET3 locus with primers METPCR and TO5r1 (see Table S2 in the supplemental material). Transformants Thomet3, Thomet4, Thomet6, and Thomet10 were selected for rescue analysis.
RACE (rapid amplification of cDNA ends) analysis. To determine the untranslated regions of the TOS9 mRNA, total RNA from opaque WUM5A cells was analyzed by both 5' RACE and 3' RACE with the SMART RACE cDNA amplification kit (Clontech, Mountain View, CA) according to the manufacturer's specifications. For 5' RACE products, the UPM primer supplied with the kit was used with either TOS9-specific primer TO5r1 or TO5r2, and for 3' RACE products, the primer TOS9f4 was used (see Table S2 in the supplemental material). The PCR products were cloned into the pGEM-T Easy vector (Promega Corp.) and sequenced.
Temperature-induced mass conversion. Cells were grown in suspension to the late exponential phase of growth at 25°C in modified Lee's medium and then diluted three- to fourfold into fresh medium at 42°C (45). Cells were removed at time intervals (i) for cell density measurements with a hemocytometer; (ii) for assessment of the time of phenotype commitment by plating onto agar, incubation at 25°C for 7 days, and measurement of the proportions of white and opaque colonies; and (iii) for assessment of TOS9 and OP4 expression by Northern analysis.
Visualization of GFP-Tos9p. GFP-labeled Tos9p fluorescence was visualized with the Bio-Rad Radiance 2000MP confocal microscope system on a Nikon TE2000U microscope equipped with the 60x Plan Apochromat water immersion objective (numerical aperture, 1.2) and a 4x digital zoom. LaserSharp 2000 (release 5.2) software was used for image acquisition and fluorescence quantitation. GFP was excited with the 488-nm argon laser line at 20% power and two-scan accumulation. The same acquisition parameters were used for all samples. 4',6'-Diamidino-2-phenylindole (DAPI) staining was performed by the methods of Hazan and Liu (14).
Western analysis of Myc transformants. Cells were washed in Dulbecco's phosphate-buffered saline (Gibco Invitrogen, Grand Island, NY) containing a protease inhibitor cocktail (P8215; Sigma, St. Louis, MO) and 1 mM phenylmethylsulfonyl fluoride. Extracts were clarified by low-speed centrifugation, and protein concentrations were determined with Coomassie Plus protein assay reagent (Pierce, Rockford, IL). Western assays were run as previously described (15). The 9E10 anti-Myc antibody developed by J. M. Bishop was obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA). The 9E10 supernatant was diluted 1:10 in TBS-T (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and incubated with the membrane for 2 h at room temperature. The membrane was then washed four times in TBS-T. The primary antibody was detected with horseradish peroxidase-labeled goat anti-mouse immunoglobulin G (Promega, Madison, WI), diluted 1:10,000 in blocking buffer (3% nonfat dry milk in TBS-T), developed with SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL), and exposed to X-ray film (Eastman Kodak, Rochester, NY).
|
|
|---|
2p for ChIP-chip analysis.
Derivatives of a
C. albicans a/
strain were generated
that expressed Myc-tagged a1 or
2 for ChIP-chip
analysis (Fig.
1A). Several derivatives of each were identified and verified by Southern
blot analysis and sequencing. As was the case for the parent strain,
neither of the two selected Myc-tagged derivatives, a1-29.1 or
2-3.1, formed opaque colonies or opaque sectors after 7 days
of incubation at 25°C (Fig.
1B, C, and D). The
frequencies of switching of the selected strains were estimated to be
less than 106, at least more than 3 orders of
magnitude lower than that of a/a and
/
strains (4,
31,
37,
40,
42), indicating that the
expressed Myc-tagged proteins functioned normally in the
a1-
2 complex in repressing switching. Western blot
analysis with anti-Myc antibody revealed similar levels of Myc-tagged
a1 and
2 expression in the respective Myc-tagged
derivatives (Fig. 1E). To
demonstrate that Myc-tagged a1 and
2 bound correctly to
target DNA sequences, chromatin immunoprecipitated with anti-Myc
antibody was tested by PCR for enrichment of the CAG1
promoter, since CAG1 is repressed by the a1-
2
complex (17). Anti-Myc
chromatin immunoprecipitates were enriched for the CAG1
promoter sequence (Fig.
1F), demonstrating that
the repressor complex containing either Myc-tagged a1 or
Myc-tagged
2 bound to an expected target.
![]() View larger version (67K): [in a new window] |
FIG. 1. The
strains used for ChIP-chip analysis normally suppressed switching.
(A) The genotype of the strains used to identify targets of
the a1- 2 repressor complex. (B, C, and D) Cells from
the parent CAI4 strain and the Myc-tagged a1 (a1-29) and
2 ( 2-3) strains formed normal white colonies and
cells with the round, white phenotype, indicating that tagged a1
and 2 fully retained repressor function. (E) Western
blot treated with anti-Myc antibody. (F) ChIP with anti-Myc
antibody and subsequent PCR of CAG1, a known target of the
a1- 2 complex reveal specific Myc-tagged a1 and
2 binding. In panel F, a minus indicates the absence of
anti-Myc antibody and a plus indicates the presence of anti-Myc
antibody in the immunoprecipitation procedure. DIC, differential
interference
contrast.
|
2 binding sites across the C.
albicans genome, a high-density oligonucleotide-tiling array
was designed that covered each sequence contig present in assembly 19
of the C. albicans genome
(19) at an average
resolution of 40 bp, for a total of 369,803 oligonucleotides, each 50
bp in length. ChIP was performed independently with epitope-tagged
a1 and
2 strains (Fig.
2), and three biological replicates were performed for each factor.
Following data acquisition, the mean signal for each oligonucleotide
was calculated and used to plot the level of immunoprecipitation
enrichment across each contig. Because of the nature of the
oligonucleotide array, clear enrichment peaks were observed that
included multiple oligonucleotides (Fig.
2).
![]() View larger version (25K): [in a new window] |
FIG. 2. MTLa1
and MTL 2 bind to discrete genomic loci throughout the
genome of C. albicans. Six examples of genomic
regions enriched by the ChIP-chip procedure with a1 (red) or
2 (green). The log2 ratios of tagged
versus untagged signals are presented for each factor below the
locations of the predicted ORFs for the genomic region (dark blue) with
the ORFs predicted to be regulated by the binding event indicated with
their systematic names. The scale above each region represents 10 kb in
1-kb
increments.
|
1.15;
Zhang et al., submitted). The ORF immediately downstream of the binding
peak was determined by using the human-curated C.
albicans genome annotation
(6) (Table1). The peak
binding site was determined from thelog2 ratios of tagged versus untagged
signal in a binding region (Fig.
2). Binding site locations
were determined as the number of nucleotides (base pairs) upstream
() or downstream (+) from the translation ATG
initiation site (Table 1).
The a1p and
2p binding sites ranged from 5,647
bp upstream from the translation initiation site to sites within an ORF
(Table
1). |
View this table: [in a new window] |
TABLE 1. a1p
and 2p binding target genes identified by ChIP-chip analysis
|
2 identified 25 genes, all of
which were also identified by Myc-tagged a1 analysis. For every
target, the peak binding site for
2p was similar to that for
a1p (Table
1).
Since it had
been hypothesized that spontaneous switching in MTL-homozygous
strains may be the result of position-effect variegation mediated by
adjacent silencing regions
(21,
41,
42,
46), the chromosome
locations of a1 and
2 binding sites were mapped in
relation to telomeres and centromeres. Six target genes (ASF1,
CPH1, 19.1384, PTH2,
STE18, and WH13) were within 50 kb of centromeres,
and two (FAR1 and PSO2) were within 50 kb of
telomeres (see Fig. S1 in the supplemental
material).
Identification of candidate MSG and MSG activator genes.
We
hypothesized that phenotypic switching would involve a metastable
switch between silent and expressed states of an MSG. In
a/
cells, switching would be repressed by the
a1-
2 corepressor complex at the MSG (Fig.
3A) or at a gene that encodes an activator of MSG metastability (Fig.
3B). Hence, in
a/
cells, the MSG would be stably locked into one of
the two states. In a/a and
/
cells,
absence of the a1-
2 complex would lead to MSG
metastability and, hence, switching (Fig.
3C and D). Northern
analysis of genes with a1-
2 binding sites was therefore
performed with a/
cells, white and opaque
/
cells, and white and opaque a/a
cells. If a gene with an a1-
2 binding site was
constitutively expressed in all cell types, it was tentatively excluded
as a candidate MSG or MSG activator gene (Fig.
3E). If a gene with an
a1-
2 binding site was silent in a/
cells but expressed in either a/a or
/
cells, it was tentatively excluded as a candidate MSG or MSG activator
gene (Fig. 3E), since
switching in both a/a and
/
cells is
similarly released from a1-
2 repression
(30,
31). If a gene was silent
in a/
cells but expressed in either the opaque or the
white type of both a/a and
/
cells, it
was considered a candidate MSG (Fig.
3E). Finally, if a gene
was silent in a/
cells but expressed in both white and
opaque a/a and
/
cells, it was
considered a candidate MSG activator gene (Fig.
3E) on the basis of the
assumption that an activator would be essential for switching in both
the white-to-opaque and opaque-to-white directions in both
a/a and
/
cells (Fig.
3E). While other
interpretations of patterns were plausible, the major ones depicted in
Fig. 3E provided a
contextual framework for initial screening.
![]() View larger version (50K): [in a new window] |
FIG. 3. Transcription
profiles were used to identify candidate MSGs and candidate activators
of MSGs. (A) Model of a1- 2 repression of MSG
expression in a/ cells. (B) Model of
a1- 2 repression of an MSG activator. (C) MSG
activation of switching in a/a or /
cells. (D) Role of an MSG activator in switching.
(E) Possible expression patterns, best interpretations of
expression patterns, and genes that fit the patterns in the different
categories. (F) Examples of gene expression patterns revealed
by Northern analysis in the different categories. Wh, white; Op,
opaque.
|
/
-opaque specific (Fig.
3C and D; Table
1). These genes were also
excluded as candidates. Only one target gene, TOS9, exhibited
an expression pattern consistent with a candidate MSG. TOS9
was expressed in neither a/
cells nor white
a/a and
/
cells; it was expressed in
opaque a/a and opaque
/
cells (Fig.
3C and D; Table
1). TOS9, which
has more recently been referred to as EAP2 in C.
albicans (27),
has homologs in Schizosaccharomyces pombe
(22) and S.
cerevisiae (50,
51). These homologs,
referred to in both strains as TOS9, have been implicated in
mating, gluconate transport, endoplasmic reticulum (ER) regulation,
budding, and cell adhesion.
Six genes, STE4,
STE18, PSO2, FAR1, CEK2, and
CAG1, exhibited expression patterns consistent with a
candidate MSG activator gene. These genes were silent in
a/
cells but expressed in both opaque and white
a/a and
/
cells (Fig.
3C and D; Table
1). Since CAG1,
STE4, and STE18 are G-protein subunits involved in
pheromone signal transduction, CEK2 is a mitogen-activated
protein kinase involved in the pheromone signal transduction pathway
and FAR1 is a regulator of pheromone-induced G1
arrest and cell polarization, they were considered unlikely MSG
activator gene candidates. This left PSO2 as the
only possible MSG activator candidate. PSO2 encoded a protein
with a deduced function in DNA cross-linking and repair and was located
within 15 kb of a telomere on chromosome 2 (see Figure S1 in the
supplemental material).
Tos9p localizes in the nucleus.
Although
TOS9 was a candidate MSG on the basis of its expression
pattern (Fig. 3), it was
not located close to either a centromere or a telomere along chromosome
1 (see Figure S1 in the supplemental material). The TOS9 ORF
encoded a putative protein of 785 amino acids. A 7,000-bp region
upstream of TOS9 was devoid of an ORF (Fig.
4A). The peaks for a1p and
2p binding in this
region were 5,647 and 5,632 bp, respectively, upstream of the ORF
(Table 1). 5' and
3' RACE analyses revealed a transcription start site 2,000 bp
upstream of the ATG start codon and a transcription termination site
174 bp downstream of the TAG stop codon (Fig.
4A), indicating a
transcript size of approximately 4.5 kb. 3' RACE analysis also
revealed a relatively short poly(A) tail of 28 residues. Divergently
transcribed ORF 19.4883, of unknown function, was approximately 7,000
bp upstream from the TOS9 ORF and 1,850 bp upstream of the
a1-
2 binding region (Fig.
4A). This gene, however,
was constitutively expressed (Table
1) and therefore excluded
as a candidate MSG or activator of an MSG. The deduced Tos9 protein
contained a putative protein kinase A binding site
(KRWTDG) between +190 and +208 bp
and a putative bipartite nuclear localization sequence
(KKNLIDKDKKKKKKAKFG) between +265 and
+318 bp (Fig.
4A).
![]() View larger version (53K): [in a new window] |
FIG. 4. Deletion
of TOS9 results in cells that cannot switch and are blocked in
the white phase. (A) Description of TOS9 and its
5' upstream region. The transcription start and stop sites and
poly(A) tail were identified by RACE analysis. The directions
of transcription of TOS9 and
the divergently transcribed gene 19.4883 are denoted by straight arrows. (B)
Differential interference contrast and fluorescence images of white
cells of strain TOGF4 which express TOS9 tagged at its carboxy
terminus with GFP. (C) Differential interference contrast and
fluorescence images of opaque cells of stain TOGF4. (D) Costaining of
DAPI and GFP in TOGF4 demonstrates that Tos9p is localized to the
nuclei of opaque cells. (E, F) UV treatment of parent strain WUM5A and
the TOS9 null mutant TOHO3 stimulated switching only in the
former. (G) TOS9 is transcribed selectively in opaque cells of
WUM5A and heterozygous mutants TOHE2 and TOHE3. It is not expressed in
TOHO3 cells, which are blocked in white. Wh, white; Op, opaque. (H) The
TOS9 null mutant rescued by transformation with the
TOS9 ORF under the regulation of the MET3 promoter
formed opaque sectors in the absence of methionine and cysteine. DIC,
differential interference
contrast.
|
TOS9 null mutants do not switch. To test whether TOS9 plays a role in switching, a TOS9 null mutant was generated with the recyclable SATr cassette and the maltose-inducible flipper in strain WUM5A (36, 47). Three heterozygous deletion derivatives, TOHE1, TOHE2, and TOHE3, were generated. The homozygous deletion derivative TOHO3 was then generated from TOHE3. Deletions were verified by Southern analysis and sequencing. When cells from 4-day-old white colonies of strain WUM5A were plated on nutrient agar at 25°C, they formed white colonies with opaque sectors at a frequency of 102 to 103 after 8 days. When cells from 4-day-old white colonies of strain TOHE2 were similarly plated, they formed opaque sectors after 8 days but at a lower frequency than WUM5A. When cells from 4-day-old colonies of strain TOHE3 were similarly plated, no sectors were observed. However, TOHE3 formed opaque sectors when treated with low doses of UV irradiation (data not shown), a treatment previously demonstrated to stimulate white-opaque switching in wild-type cells (32). Cells from the opaque sectors of TOS9 heterozygous deletion mutants exhibited the typical opaque phenotype.
Colonies of the TOS9
homozygous deletion mutant TOHO3 did not produce opaque sectors, even
after 14 days at 25°C. Treatment with low doses of UV
irradiation, which induced switching to the opaque phase in parallel
cultures of parent strain WUM5A (Fig.
4E), did not induce
switching in TOHO3 (Fig.
4F). Northern analysis
revealed that TOS9 was selectively transcribed in the opaque
phase of WUM5A, TOHE2, and TOHE3 but not in TOHO3 (Fig.
4G), which appeared to be
blocked in the white phase. This latter conclusion was supported by the
observations, first, that WH11, a white phase-specific gene,
was selectively expressed in TOHO3 (Fig.
4G) and, second, that
a-pheromone, which induces cohesiveness in white but not opaque
/
cells, a first step in biofilm formation
(9), induced cohesiveness
between TOHO3 cells (data not shown).
Heterozygous and homozygous deletion mutants of the candidate MSG activator PSO2 were generated by the same strategy used to generate the corresponding mutants in TOS9. They were also similarly verified. Cells of the PSO2 heterozygous mutant and null mutant switched to the opaque phase at the same frequency as parent strain WUM5A (data not shown). For that reason, PSO2 was excluded as a candidate MSG activator gene.
Misexpression of TOS9 in white a/a cells (TOS9/TOS9) causes mass conversion to the opaque state. The phenotype of the null mutant TOHO3 indicated that TOS9 expression was essential for a switch from white to opaque. If TOS9 played a role in the actual switching event, then misexpression in a white cell should drive the phenotype to opaque. To test this possibility, strain WUM5A (TOS9/TOS9) was transformed with a construct in which the TOS9 ORF was under the regulation of a tetracycline (doxycycline)-inducible promoter (34), generating strain Wr1. The doxycycline-regulated construct was targeted ectopically to one of the two ADH1 alleles (33). A control strain, Wnm1, was generated in which the GFP rather than the TOS9 ORF was placed under the regulation of the doxycycline promoter. White Wr1 cells plated on nutrient agar lacking doxycycline formed predominantly (>99%) white colonies (Fig. 5A), which produced opaque sectors after 8 days at a frequency of 102 to 103, similar to that of parent strain WUM5A. In contrast, white Wr1 cells plated on nutrient agar containing doxycycline at 50 µg/ml, the concentration used in previous studies to activate this promoter (34), formed almost exclusively (>99%) pink colonies (Fig. 5B). The proportion of opaque and white cells in these pink colonies varied between 50:50 and 80:20 (Fig. 5B). When cells from these pink colonies were replated on agar lacking doxycycline, the resulting colonies exhibited both the opaque and the white phenotypes (Fig. 5B). The red colonies contained almost predominantly opaque cells, and the white colonies contained predominantly white cells (Fig. 5B). When cells from pink colonies were replated on agar containing 50 µg/ml doxycycline, they formed both red and pink colonies (data not shown). The red colonies contained almost exclusively opaque cells, and the pink colonies contained a mixture of opaque and white cells (data not shown). An experiment in which the concentration of doxycycline was varied revealed that while 80 µg/ml induced switching in 80% of a white cell population, 200 µg/ml induced nearly all cells (>95%) to switch to the opaque state (Fig. 5D). Control Wnm1 cells behaved like parent cells. These results demonstrated that misexpression of TOS9 in white MTL-homozygous cells induced mass conversion to the opaque state in a dose-dependent fashion, indicating that TOS9 plays a role in inducing the switch from white to opaque.
![]() View larger version (48K): [in a new window] |
FIG. 5. Misexpression
of TOS9 in white cells causes mass conversion to the opaque
phase. TOS9 was placed under the control of a tetracycline
(doxycycline)-inducible promoter at an ectopic site in
TOS9/TOS9 parent strain WUM5A to generate strain Wr1.
(A, B, C) White, pink, and red colonies of Wr1 cells treated with 0,
50, and 200 µg/ml doxycycline, respectively, contained white,
white plus opaque, and opaque cells, respectively. Replating in the
absence of doxycycline demonstrated white, a mixture of white and
opaque, and opaque colonies, respectively. (D) Dose-response
curve of doxycycline induction of the switch from white to opaque in
strain Wr1. Data from two experiments, each including 200 colonies per
doxycycline concentration, were pooled. The data from the two were
highly
similar.
|
Temperature-induced mass conversion and TOS9 expression. Given that an increase in TOS9 expression initiates and drives a switch from white to opaque, we expected that a decrease in TOS9 expression would initiate and drive the reverse switch from opaque to white. To test this prediction, we first measured TOS9 expression when parent WUM5A opaque cells were induced to undergo mass conversion to white by increasing the temperature from 25°C to 42°C (37, 40, 45). To monitor the point of commitment to the white phenotype at 42°C, cells were replated on nutrient agar at time intervals and incubated at 25°C and the phenotype of colonies was assessed after 4 days. The time period at 42°C after which a return to 25°C resulted in white rather than opaque colony formation was considered the point of commitment to the white phenotype. Cells in the population began committing to the white phenotype after 4 h, reaching 70% after 6.5 h, concomitant with the kinetics of the second cell doubling (Fig. 6A), as previously reported (42, 45). The TOS9 transcript decreased to a negligible level within 30 min after cells were shifted from 25°C to 42°C, partially rebounded at 2 h, and then gradually decreased to a low level by 5.5 h (Fig. 6B). When cells were then returned from 42°C to 25°C prior to the commitment point (0.5, 2, and 3 h) and incubated for 2 h at 25°C, the TOS9 transcript level was reestablished, but when they were shifted after the point of phenotypic commitment, the level was not reestablished (Fig. 6B). This pattern was similar but not identical to that of OP4 (Fig. 6B), an opaque-specific gene, which decreased to a negligible level 0.5 h after the initial shift from 24°C to 42°C and remained negligible at the higher temperature (Fig. 6B). As was the case for TOS9, a shift back to 25°C prior to, but not after, phenotypic commitment reestablished the OP4 transcript level (Fig. 6B).
![]() View larger version (43K): [in a new window] |
FIG. 6. When
opaque cells were induced to mass convert to white by a shift from
25°C to 42°C, the TOS9 transcript and protein
levels decreased during the period preceding phenotypic commitment (the
switch) to the white phenotype. The switch event was inhibited by
addition of hydroxyurea just prior to the commitment event. It was also
inhibited by misexpression of TOS9 after the temperature
shift. (A) The kinetics of phenotypic commitment to the white
phase after an opaque cell population is shifted from 25°C to
42°C. The majority of cells commit to the white phase in
concert with the second cell doubling. (B) The TOS9
transcript level decreases to a negligible level after 0.5 h
at 42°C, rebounds at 2 h, and then decreases to a
very low level by 5.5 h. Reexpression to the original level
before the temperature shift can be induced by reducing the temperature
from 42°C to 25°C up to the point of phenotypic
commitment to the white phase (1 h, 3 h) but not after
phenotypic commitment (7 h). (C) Tos9p fluorescence decreases
during the period preceding phenotypic commitment in strain Wr1. A
reduction in temperature at 3 h, but not at 7 h,
reestablishes Tos9p fluorescence in the nucleus. (D)
Misexpression of TOS9 at 42°C, by doxycycline
induction of strain Wr1, blocks the temperature-induced switch to white
(data in bold print). (E) Addition of hydroxyurea at
3 h, but not at 6 h, blocks commitment (the switch)
to the white phase. Wh, white; Op,
opaque.
|
To test whether the decrease in Tos9p is essential for temperature-induced mass conversion, TOS9 was misexpressed after opaque cells were shifted from 25°C to 42°C. Strain Wr1 was used, which harbors, in addition to TOS9 at the native locus, an ectopic copy of TOS9 under control of the doxycycline-inducible promoter. In the absence of doxycycline, Wr1 underwent mass conversion, but in the presence of doxycycline, mass conversion was inhibited (Fig. 6D, inhibition data in bold print). These results demonstrated that the transition from opaque to white required down-regulation of TOS9.
Since commitment to the white phase (i.e., the switch from opaque to white) depended on a decrease in Tos9p, which occurred prior to the second cell doubling (42, 45), the possibility existed that the decrease in Tos9p and DNA replication, which preceded the second cell doubling, were both essential for the switch to occur. We therefore tested whether hydroxyurea, an inhibitor of DNA replication (13, 39), added just prior to the second cell doubling, inhibited the commitment event. Addition prior to commitment (0.5, 2, and 3 h) inhibited it (Fig. 6E). Cells inhibited by hydroxyurea still exhibited the same low level of Tos9p. These results demonstrated that a decrease in Tos9p was not sufficient for a switch to proceed. Cells still had to undergo DNA replication.
|
|
|---|
2 binding in an
a/
cell. Thirteen of these genes had known or deduced
mating-related functions. A prior microarray analysis of transcription
had demonstrated that 6 of these 13 genes were repressed in
a/
cells and expressed in MTL-homozygous cells
(49). Of the 52 targets
of the a1-
2 corepressor, 25 provided distinct Northern
blot hybridization patterns, and of these latter genes, only 1,
TOS9, fit the predicted expression profile of an MSG while 6
fit the predicted expression pattern of an MSG activator. Of this
latter group, five encoded proteins with specific functions in the
pheromone transduction pathway and therefore were tentatively excluded
as candidates, leaving only one candidate, PSO2. Mutant
analysis demonstrated that while TOS9 was essential for
switching, PSO2 was not. TOS9 encoded a putative
protein of 785 amino acids of unknown function. Recently, this gene was
identified in a screen for C. albicans genes that
promote adhesion and pseudohypha formation in an S.
cerevisiae flo8
mutant deficient in these
characteristics (27).
They referred to the gene as EAP2 for its capacity to
stimulate adhesion of the flo8
mutant to epithelium.
The TOS9 homolog in S. pombe regulates
mating in a cyclic-AMP-independent fashion
(22) and is an inducer of
gluconate transport (8).
The homolog in S. cerevisiae has been implicated in
regulation of the smooth ER
(50), budding
(51), and cell adhesion
(27). TOS9 was
one of the six genes that had previously been identified by microarray
analysis to be repressed in a/
cells and expressed in
opaque a/a cells
(49). By Northern
analysis, we confirmed that TOS9 was silent in
a/
cells and transcribed exclusively in opaque cells,
and not in white cells, of MTL-homozygous strains of
C. albicans. By tagging Tos9p with GFP, we found that
the protein was expressed only in opaque cells and localized to the
nucleus, suggesting that it plays a role in gene regulation and/or DNA
replication. The TOS9 locus is unusual. The TOS9 ORF
is preceded by a 7,000-kb noncoding region. The a1-
2
binding site was approximately 5,647 bp upstream of the TOS9
ORF (Fig. 4A). The binding
site was also upstream of a divergently transcribed ORF, 19.4883, of
unknown function. Since this latter gene was constitutively expressed,
it was excluded as a candidate MSG or MSG activator. RACE analysis
revealed that the transcription start site of TOS9 was
approximately 2,000 bp upstream of the ORF and 3,647 bp downstream of
the a1-
2 binding site. It contained no intron. The
estimated size of the TOS9 transcript was therefore 4.5 kb. We
found that expression of an ectopic copy of the TOS9 ORF which
lacked the extensive upstream region drove switching in the
white-to-opaque direction under regulation of a tetracycline-induced
promoter and blocked switching in the opaque-to-white direction under
the regulation of the same promoter. Therefore, the 5'
untranslated region of the TOS9 mRNA was not essential for
TOS9 induction of the white-to-opaque switch or inhibition of
the opaque-to-white switch. It may, however, play a role during
spontaneous switching in the regulation of mRNA half-life, a
possibility now under analysis. The TOS9 ORF contained a
putative protein kinase A binding site, suggesting that Tos9p may be
regulated by phosphorylation. It also contained a nuclear localization
signal, which was most probably responsible for nuclear
localization. Deletion of one of the two TOS9 alleles did not block spontaneous switching to the opaque phenotype, but it did decrease the switching frequency, suggesting that the TOS9 transcript level, and therefore the level of Tos9p, regulated the frequency of spontaneous switching. Deletion of both TOS9 alleles resulted in the loss of switching and a block in the white phenotype. UV treatment, which stimulates switching by at least 2 orders of magnitude in wild-type cells (32), did not stimulate switching from white to opaque in the TOS9 null mutant, indicating that TOS9 was essential for the white-to-opaque transition. Furthermore, misexpression of ectopic TOS9 in white cells with an intact TOS9 locus caused mass conversion of the cell population to opaque. Resultant opaque cells were stable in the absence of doxycycline induction. This suggested that once stimulated in the white phase by misexpression of ectopically expressed TOS9 (self-induction), the native TOS9 gene continued to be expressed and, through this expression, maintained the opaque phenotype. When cells of the TOS9 null mutant were transformed with the same doxycycline-inducible TOS9 construct at the same ectopic locus and induced with doxycycline, they did not switch to the opaque phase, suggesting that the native locus was required. However, when cells of the TOS9 null mutant were transformed with a construct in which the TOS9 ORF was under the regulation of the apparently stronger MET3-repressible promoter, they stably switched to the opaque state.
We have also demonstrated that during temperature-induced mass conversion from opaque to white, the TOS9 transcript and protein decrease to low levels prior to phenotypic commitment. Misexpression of the TOS9 ORF under control of the tetracycline-inducible promoter at an ectopic locus after an increase in temperature blocked the switch from opaque to white, suggesting that the level of Tos9p must decrease below a threshold for the switch from opaque to white to be initiated. The commitment event of an opaque-to-white switch, however, occurred at the time of second cell doubling following the increase in temperature (45) and presumably follows a second round of DNA replication (42). Inhibition of the second round of DNA replication with hydroxyurea, like misexpression of TOS9, blocked the temperature-induced switch to white without reestablishing Tos9p levels. This suggests that a switch requires two events, first, a decrease in the level of Tos9p and, second, DNA replication.
These results suggest a working model for spontaneous switching in which TOS9 plays a central role. Based upon the effects on switching frequency of the histone deacetylase inhibitor trichostatin A and deletion of the histone deacetylases HDA2 and RPD3 (21, 46) and upon the dependency of the opaque-to-white switch on the second round of DNA replication demonstrated here, we hypothesize that stable switching events in both the white-to-opaque and opaque-to-white directions involve a change at a switch locus between the white and opaque chromatin states. We further hypothesize, on the basis of the functional analysis of TOS9 presented here, that Tos9p directly or indirectly causes this change in chromatin state. The site of this change has not been established and has therefore been referred to in the model as gene X. While there is reason to believe that TOS9 may not be the site of a TOS9-induced change in chromatin state, including the observations that it is self-inductive and can effect a switch through misexpression at an ectopic locus in the absence of the entire upstream region, including the large untranscribed region, it cannot be excluded. The product of gene X would be differentially expressed in the two switch phases and would regulate the patterns of phase-specific gene expression and, hence, phenotype (Fig. 7).
![]() View larger version (29K): [in a new window] |
FIG. 7. A
model for spontaneous switching between the white and opaque phases.
The salient features of the model are the following. Spontaneous
self-induction of TOS9 expression in white leads to a change
in chromatin state of an as-yet-unidentified switching locus, gene X.
This change requires DNA replication. Continued expression of
TOS9 maintains the opaque chromatin state and hence the opaque
phenotype. A spontaneous decrease in TOS9 expression below a
threshold results in a change in gene X from an opaque to a white
chromatin state and, hence, a change to the white phenotype. The change
in chromatin state of gene X activates its expression, but it is not
clear if activation is in the white or the opaque state. Gene X must
then regulate the pattern of phase-specific gene expression and
phenotype. TOS9 has not been excluded as the site of change.
The correlation of commitment and the second cell doubling in the
opaque-to-white transition suggests that opaqueness is the recessive
state and whiteness is the dominant state, as previously proposed
(41).
|
This research was supported by NIH grants AI2392 to D.R.S. and RO1-CA077808-9-13 to M.S.
Published ahead of print on 1 September 2006. ![]()
Supplemental material for this article may be found at
http://ec.asm.org/. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»